Synopsis:
The vast majority of available evidence on the efficacy, effectiveness and safety of hydroxyurea in childhood sickle cell anaemia (SCA) is mostly from high-income countries. The conclusions drawn from this study would be useful in guiding hydroxyurea use in other less developed countries with limited resources.